PUBLISHER: The Business Research Company | PRODUCT CODE: 1948260
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948260
Spinal cord stimulation (SCS) devices are implantable medical devices that help manage chronic pain by delivering gentle electrical pulses to the spinal cord. These pulses disrupt pain signals before they reach the brain, providing relief. SCS devices combine advanced neurotechnology with customizable programming, offering a minimally invasive treatment for conditions such as neuropathic pain and failed back surgery syndrome.
The primary types of SCS devices include implantable and non-implantable stimulators. Implantable spinal cord stimulators are surgically placed under the skin and deliver electrical pulses directly to the spinal cord, interfering with pain signals to alleviate chronic discomfort. SCS devices are further categorized into rechargeable and non-rechargeable types. They are used for various applications, including failed back surgery syndrome, complex regional pain syndrome, degenerative disc disease, unsuccessful disk surgery, and other chronic pain conditions. End users include hospitals, ambulatory surgical centers, and neuro clinics.
Tariffs are impacting the spinal cord stimulation devices market by increasing costs of electronic components, implantable leads, and battery systems. Implantable and rechargeable device segments are most affected, especially in North America and Europe. However, tariffs have encouraged domestic manufacturing, modular device designs, and supply chain diversification.
The spinal cord stimulation devices market research report is one of a series of new reports from The Business Research Company that provides spinal cord stimulation devices market statistics, including spinal cord stimulation devices industry global market size, regional shares, competitors with a spinal cord stimulation devices market share, detailed spinal cord stimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the spinal cord stimulation devices industry. This spinal cord stimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The spinal cord stimulation devices market size has grown strongly in recent years. It will grow from $2.97 billion in 2025 to $3.23 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rise in chronic pain cases, failed back surgery syndrome prevalence, opioid alternative demand, neurology procedure growth, implantable device acceptance.
The spinal cord stimulation devices market size is expected to see strong growth in the next few years. It will grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to AI-driven stimulation algorithms, growth in wearable stimulators, expansion of pain management clinics, long-term pain therapy adoption, remote device monitoring. Major trends in the forecast period include personalized pain management therapy, rechargeable neurostimulation devices, minimally invasive neuromodulation, wireless programming systems, multi-lead stimulation technology.
The increasing prevalence of chronic pain is expected to propel the growth of the spinal cord stimulation (SCS) devices market. Chronic pain, characterized by persistent pain lasting 12 weeks or longer, often arises from conditions such as arthritis, neuropathy, or low back pain. This increase is driven by factors such as an aging population, lifestyle changes, chronic health conditions, and injuries or trauma. SCS devices help alleviate chronic pain by delivering electrical impulses to modify pain signals, offering relief for long-term conditions. For example, in November 2024, the Centers for Disease Control and Prevention (CDC) reported that in 2023, 24.3% of adults experienced chronic pain, with 8.5% reporting high-impact chronic pain, accounting for 34.9% of chronic pain cases. These trends underscore the rising demand for SCS devices in managing chronic pain effectively.
Major companies operating in the spinal cord stimulation devices market are increasingly emphasizing advanced technologies, such as AI-driven personalization, to enhance therapy responsiveness, enable adaptive pain control, and deliver more accurate, patient-specific treatment for individuals experiencing chronic pain. AI-driven spinal cord stimulation (SCS) systems utilize machine-learning models trained on device- and patient-generated data to adjust stimulation settings in near real time, with the goal of maintaining optimal pain relief while minimizing the programming workload for clinicians. For example, in September 2024, Nevro Corp., a US-based medical device company, introduced HFX iQ with HFX AdaptivAI, an AI-enabled SCS platform that leverages millions of data points and adaptive algorithms to personalize 10 kHz therapy and facilitate remote clinician monitoring. This platform is designed to automatically modify stimulation parameters based on individual patient responses, improving pain management outcomes and reducing the need for frequent in-person programming visits. By incorporating real-time insights and remote management capabilities, HFX iQ seeks to improve treatment precision, streamline clinical workflows, and deliver a more consistent and effective therapy experience for patients with chronic pain.
In November 2023, Boston Scientific Corporation strengthened its chronic pain treatment portfolio by acquiring Relevant Medsystems Inc. for $850 million. This acquisition added basivertebral nerve ablation therapy, provided by Relevant Medsystems, to Boston Scientific's suite of chronic pain solutions, which includes spinal cord stimulation devices. Relevant Medsystems, known for its innovative chronic pain management technologies, enhances Boston Scientific's ability to offer comprehensive treatment options for patients suffering from persistent pain.
Major companies operating in the spinal cord stimulation devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Nevro Corp., Bluewind Medical, NeuroPace Inc., Vertos Medical Inc., SPR Therapeutics Inc., Saluda Medical Pty Ltd., Stimwave Technologies Inc., Nuvectra Inc., Soterix Medical Inc., Synapse Biomedical, ONWARD Medical NV, NeuroSigma Inc., Nalu Medical Inc., Neurostim Technologies, SpineX Inc., Aleva Neurotherapeutics SA, GTX Medical BV
North America was the largest region in the spinal cord stimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal cord stimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the spinal cord stimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The spinal cord stimulation devices market consists of sales of implantable pulse generators (IPGs), leads and electrodes, MRI-compatible SCS devices, and hybrid stimulation systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Spinal Cord Stimulation Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses spinal cord stimulation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for spinal cord stimulation devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The spinal cord stimulation devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.